

# 2024 STI Update

Hillary Liss, MD (<u>hliss@uw.edu</u>) Harborview Medical Center University of Washington (206) 744-1035



Last updated April 24, 2024

Follow 3 easy steps to protect your patients' health:





Morbidity and Mortality Weekly Report July 23, 2021

Sexually Transmitted Infections Treatment Guidelines, 2021



• No conflicts of interests or relationships to disclose

#### Disclaimer

Funding for this presentation was made possible by U1OHA29296 from the Human Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. *Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.* 



THE STATE OF STIS IN THE UNITED STATES, 2022

CDC's 2022 STI Surveillance Report underscores that STIs must be a public health priority **1.6 million** CASES OF CHLAMYDIA 6.2% decrease since 2018

648,056 CASES OF GONORRHEA 11% increase since 2018 LEARN MORE AT: www.cdc.gov/std,


**207,255** CASES OF SYPHILIS 80% increase since 2018

**3,755** CASES OF SYPHILIS AMONG NEWBORNS

183% increase since 2018

ANYONE WHO HAS SEX COULD GET AN STI, BUT SOME GROUPS ARE MORE AFFECTED O YOUNG PEOPLE AGED 15-24

- **D GAY & BISEXUAL MEN**
- **O PREGNANT PEOPLE**
- **O** RACIAL & ETHNIC MINORITY GROUPS



Disease	Cases					Percent Change	
	2018	2019	2020	2021	2022	5 Year	1 Year
Chlamydia	1,758,668	1,808,703	1,579,885	1,644,416	1,649,716	-6.2	0.3
Gonorrhea	583,405	616,392	677,769	710,151	648,056	11.1	-8.7
Syphilis (All Stages)	113,739	127,943	131,797	173,858	203,500	78.9	17.0
Congenital Syphilis	1,325	1,882	2,162	2,875	3,755	183.4	30.6
Total Reported STIs	2,457,137	2,554,920	2,391,613	2,531,300	2,505,027	1.9	-1.0

There are no shortcuts, and we have to meet people where they are. Some people face tremendous barriers to STI prevention and health services. So, the most important work is often outside the clinic, whether it be reaching out to communities with testing, interviewing patients to offer services to their partners, or delivering treatment directly to someone.

- Laura Bachmann, MD, MPH, Acting Director, CDC's Division of STD Prevention

# We have a plan! (June 2023)

Focused on: Chlamydia Gonorrhea Syphilis HPV/HPV vaccination HSV is coming!

Sexually Transmitted Infections



for the United States | 2021-2025

#### VISION

The United States will be a place where sexually transmitted infections are prevented and where every person has high-quality STI prevention, care, and treatment while living free from stigma and discrimination.

This vision includes all people, regardless of age, sex, gender identity, sexual orientation, race, ethnicity, religion, disability, geographic location, or socioeconomic circumstance.

#### **B.** Goals

In pursuit of this vision, the STI Plan establishes five goals:



1. Prevent new STIs

- 2.1
- 2. Improve the health of people by reducing adverse outcomes of STIs



3. Accelerate progress in STI research, technology, and innovation



4. Reduce STI-related health disparities and health inequities




5. Achieve integrated, coordinated efforts that address the STI epidemic



Sexually Transmitted Infections (STI) National Strategic Plan: 2021-2025 (hhs.gov)

#### New-ish 2021 CDC STI Guidelines



Mobile app now available for Apple and Android devices Search "STI Tx Guide"

https://www.cdc.gov/std/treatment-guidelines/provider-resources.htm#MobileApp

https://www.cdc.gov/std/treatment-guidelines/default.htm

### What's in a Name?

# STD

- Sexually transmitted *disease*
- Refers to disease or illness
- Implies sickness

# STI

- Sexually transmitted *infection*
- Refers to pathogen
- Often asymptomatic

#### **CDC STI Treatment Guideline Development**

- Evidence-based on principal outcomes of STI therapy
- "Recommended" regimens preferred over "alternative" regimens
- Treatments alphabetized unless there is a priority of choice
- Released July 2021


#### Some clarifications and caveats...

- CDC uses gender-based recommendations
  - Includes a section about transgender and gender diverse persons
  - Screening guidelines written for "women" and "men"
  - For clinical purposes, consider anatomy and anatomic sites of exposures
- Graphic images ahead
- Racism, not race/ethnicity, creates and perpetuates health disparities

# THE INS AND OUTS OF SCREENING: 2021 CDC RECOMMENDATIONS



## STI Screening: Don't Be This Person!



### New Sexual History Taking Guide: New 5 P's



1. Partners

What are the genders of your partners...

- 2. Practices
- 3. Protection from STIs
- 4. Past history of STIs
- 5. Pregnancy intention (new)


Previously "prevention"

#### Additional questions for identifying HIV and viral hepatitis risk:

- Have you or any of your partner(s) ever injected drugs?
- Is there anything about your sexual health that you have questions about?

https://www.cdc.gov/std/treatment-guidelines/clinical-risk.htm

## Updates to Hepatitis C (HCV) screening





\*unless local prevalence is <0.1%

### STI Screening for Women (WSM and WSW)

#### Women under 25 years of age

Chlamydia/gonorrhea

HIV at least once

Hep C at least once if  $\geq$  18 yo (unless prevalence of Hep C < 0.1%)

Women 25 years of age and older

Chlamydia/gonorrhea if at risk

HIV at least once

Hep C at least once (unless prevalence of Hep C < 0.1%)

Pregnant persons

Chlamydia (<25 years of age, or older women if at risk, and retest during 3<sup>rd</sup> trimester) Gonorrhea (<25 years of age, or older women if at risk, and retest during 3<sup>rd</sup> trimester) HIV at 1<sup>st</sup> antenatal visit, and in 3<sup>rd</sup> trimester, if at risk Syphilis serology at 1<sup>st</sup> antenatal visit, in 3<sup>rd</sup> trimester, and at delivery, if at risk (WA DOH)

HepB sAg

Hep C (unless prevalence of Hep C < 0.1%) WITH EVERY PREGNANCY

#### Screening not recommended for M. genitalium or trichomonas

# STI Screening in Men who Have Sex with Women (MSW)

- No routine screening in the community
  - Except HIV (age 15-65 and if seeking STI testing) and Hepatitis C if age ≥18
- CDC says consider screening for:
  - CT in "young men" in adolescent clinics, correctional facilities, and STI clinics or in populations with high burden of infection
  - Syphilis if increased risk (includes history of incarceration, age <29)
  - Hepatitis B if at increased risk (sexual or percutaneous exposure)

## STI Screening for MSM

- HIV\*
- Syphilis\*
- Urethral GC and CT\*
- Rectal GC and CT (if receptive anal sex)\*
- Pharyngeal GC (if oral sex)\*
- Hepatitis B (HBsAg, HBV core ab, HBV surface ab)
- Hepatitis C: (At least once if ≥ 18 yo, unless prevalence of infection < 0.1%)</li>
- Anal cancer: annual digital anorectal exam may be useful (no anal Pap rec yet)
  - BUT STAY TUNED!!! Awaiting guidelines...
- HSV-2 serology (consider)

\*At least annually, more frequent (every 3-6 months) if multiple/anonymous partners, drug use, or partners with risk

#### Routine screening not recommended for M. genitalium

#### **STI Screening for Transgender Persons**

Based on current anatomy and gender of sex partners

- Offer HIV screening to all transgender persons
- TG persons who have sex with cisgender men or transgender women, at similar risk for STIs as cis-MSM

Transgender women post vaginoplasty

GC/CT (all sites of exposure: oral, anal, genital)

(urine vs neovaginal swab not specified, best specimen type based on tissue type used to construct neovagina)

Transgender men post metoidioplasty

 If vagina still present and need to screen for STIs, cervical (or front hole) swab should be used as "a urine specimen will be inadequate for detecting cervical infections"

# EXTRA-GENITAL SCREENING: IF YOU JUST CHECK THE PEE, YOU'LL MISS GC AND CT...



#### What is "Extragenital" Screening?

- Extragenital screening = testing for STIs at any body site other than genitourinary (urethral/urine/vaginal/cervix)
- Usually refers to rectal and oropharynx
- Typically for gonorrhea and/or chlamydia only
- Previously recommended routinely only for MSM, but now *permissive* for other individuals

### Importance of Extragenital GC/CT Infections

#### Transmission

- 30% of symptomatic gonococcal urethritis is attributable to oro-pharyngeal exposure<sup>1</sup>

#### HIV Transmission

- Can increase risk of acquisition<sup>2-4</sup>

#### • Treatment can differ

- Pharyngeal GC<sup>5</sup>
  - Ceftriaxone > Cefixime
- Rectal CT<sup>6</sup>
  - Doxy >>> Azithromycin

1. Barbee et al, *STI*, 2015; 2. Vaughan, *BMC Med Res Methodol*, 2015; 3. Kelly, *AIDS Res Hum Retroviruses*, 2015; 4. Jin, *JAIDS*, 1999; 5. Moran, *STD* 1995; 6. Kong, *JAC*, 2015


#### Extragenital Gonorrhea & Chlamydia is Common

- Among MSM, high rates of extra-genital GC & CT
  - Pharyngeal GC: 9.2%<sup>1</sup>
  - Rectal GC: 9.7%<sup>3</sup>
  - Rectal CT: 12%<sup>3</sup>
- The majority of infections are asymptomatic
  - 92% of pharyngeal GC<sup>2</sup>
  - 84-86% of rectal GC<sup>2</sup>

Kent CK. CID 2005
Morris, CID 2006
Barbee, STD 2014

#### Checking Urine Alone Insufficient in MSM


#### FOR PROVIDERS: DID YOU KNOW?



STD Surveillance Network, July 2010- June 2012, STD clinic data for 11 SSuN jurisdictions. Patton, et al. Clin Infect Dis. March 2014.



### Don't forget the triple dip: STI Screening for MSM



Annually for all sexually active MSM Every 3-6 months for high-risk MSM

## STDs predict future HIV Risk among MSM


Rectal GC or CT

# 1 in 15 MSM were diagnosed with HIV/ within

1 in 15 MSM were diagnosed with HIV within 1 year.\*

Primary or Secondary Syphilis

No rectal STD or syphilis infection



\*STD Clinic Patients, New York City. Pathela, CID 2013:57; \*\*Matched STD/HIV Surveillance Data, New York City. Pathela, CID 2015:61

## What about extragenital screening for women?

- Not routinely recommended by CDC STD Guidelines
  - BUT MORE PERMISSIVE LANGUAGE IN THE 2021 GUIDELINES
  - Rectal CT and pharyngeal/rectal GC "can be considered in females based on reported sexual behaviors and exposure, though shared clinical decision…"
- Meta-analysis of 14 studies of rectal testing<sup>1</sup>
  - Overall 6.0% rectal CT positivity
  - When urogenital CT detected 68.1% also rectal positive
  - 2.2% isolated rectal CT
  - Rectal CT not associated with reported anal intercourse
- Can increase rates of chlamydia case-finding
- Should be treated if found



#### **TESTYOURSELF** Visual Guides for Self-Collection



Now available in 22 languages!


Visit <a href="https://www.uwptc.org/visual-guides">https://www.uwptc.org/visual-guides</a> for free posters for your clinic



## CHLAMYDIA



# Chlamydia – Rates of Reported Cases by State, United States and Territories, 2022




▶\* Per 100,000

You diagnose a 24 yo man who has sex with men with rectal CT after implementing a self-testing program in your clinic. What is the best treatment for this?

- 1. Azithromycin 1 gm orally once
- 2. Doxycycline 100 mg twice daily for 7 days
- 3. Either is fine


#### Doxycycline vs Azithromycin for Urogenital Chlamydia



Slide credit: Dr. Will Geisler

#### Doxycycline vs Azithromycin for Rectal Chlamydia


Efficacy



Slide credit: Dr. Will Geisler

Dombrowski J et al, CID 2021

#### First RCT of Doxycycline vs Azithromycin for Rectal CT: Microbiologic cure at 4 weeks



#### Chlamydia Treatment: Urogenital/ Rectal/ Pharyngeal

Change in 2021 STI Treatment Guidelines

Recommended regimens (non-pregnant):

Doxycycline 100 mg orally twice daily for 7 days\*

Alternative regimens (non-pregnant):

- Azithromycin 1 g orally in a single dose OR
- Levofloxacin 500 mg orally once daily for 7 days

\*Doxycycline delayed-release 200 mg, once-daily dosing for 7 days effective for urogenital CT. More costly but lower frequency GI side effects than standard doxycycline.

#### Chlamydia Treatment: Pregnancy

Recommended regimen (pregnant\*):

• Azithromycin 1 g orally in a single dose

Alternative regimens (pregnant\*):

• Amoxicillin 500 mg orally three times a day for 7 days

\* Test of cure at 3-4 weeks only in pregnancy

## But Azithromycin, How We Love Thee...

- Advantages
  - Can be dispensed in clinic, directly-observed therapy
  - Single dose
    - Better for adherence issues
    - More discreet, better for adolescents, confidentiality
    - Better tolerated, fewer adverse effects
  - Safe in pregnancy and breastfeeding

\*NOTE: CDC STD Treatment Guidelines are guidance not prescriptive. Clinicians may use judgment with clinical decision making. Sure feels like there are a lot of changes for me in the 2021 CDC STI Guidelines!



Chlamydia






Gonorrhea



## GONORRHEA




Gonorrhea – Rates of Reported Cases by State, United States and Territories, 2022



▶\* Per 100,000

Gonorrhea – Estimated Rates of Reported Gonorrhea Cases by MSM, MSW, and Women, STD Surveillance Network (SSuN), 2010-2019



- ▶ \* Per 100,000 population
- NOTE: Estimate based on weighted analysis of data obtained from interviews (n=28,979) conducted among a random sample of reported gonorrhea cases. Sites include Baltimore, Philadelphia, New York City, Washington State, San Francisco, and California (excluding San Francisco).
- > ACRONYMS: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only

You get a call from the lab telling you that the patient you tested for STIs yesterday has a positive gonorrhea NAAT. Before deciding on treatment, what do you need to know?

- 1. Site of infection
- 2. Patient's weight
- 3. Drug allergy history
- 4. Chlamydia test result
- 5. All of the above

### \*New\* Gonorrhea Treatment Guidelines

for uncomplicated infections

#### Ceftriaxone <u>500</u> mg IM x 1 for persons weighing <150 kg\*

\*For persons weighing ≥ 150 kg, 1 g of IM ceftriaxone should be administered

However, if chlamydia has <u>not</u> been excluded, treat for chlamydia with:

#### Doxycycline 100 mg PO BID x 7 days


For pregnancy, allergy, or concern for non-adherence, 1 g PO \_\_\_\_\_azithromycin x 1 can be used\_\_\_\_\_

- No longer recommending dual therapy for GC with azithromycin
- Test-of-Cure at 7-14 days post treatment for pharyngeal gonorrhea

Update to CDC's Treatment Guidelines for Gonococcal infection, 2020; MMWR

### \*New\* Alternative Gonorrhea Treatment

for uncomplicated infections of the cervix, urethra, and rectum *if ceftriaxone is not available*:



No reliable alternative treatments are available for pharyngeal gonorrhea

Update to CDC's Treatment Guidelines for Gonococcal infection, 2020; MMWR

## Any downside to the alternative/allergy regimen?

- Nausea was common
  - 27% for gentamicin + azithro
  - 37% for gemifloxacin + azithro
- Also vomiting
  - 3% and 7% in each group vomited <1 hr after administration




## Rationale for GC Treatment Changes

- Growing GC resistance
- Antibiotic stewardship
- Pharmacokinetics/pharmacodynamics
- Decreasing efficacy of azithromycin against CT

• And low ceftriaxone resistance in the US...for now

# More than half of GC isolates are resistant to at least one antibiotic

#### Prevalence of Resistant or Decreased Susceptibility of *N. gonorrhoeae* Isolates to Antimicrobials, GISP, 2009 and 2019\*



\* 2019 data are preliminary


Slide courtesy Sancta St. Cyr National STD Prevention Conference 2020

## Why Remove Azithromycin? Growing Resistance



#### Neisseria gonorrhoeae causes gonorrhea, a sexually transmitted disease (STD) that can result in life-threatening ectopic pregnancy and infertility, and can increase the risk of getting and giving HIV.

## Rise in GC Isolates with Decreased Susceptibility to Azithromycin (~5%) Gonococcal Isolate Surveillance Project (GISP), 2010–2019



Clinical Infectious Diseases


MAJOR ARTICLE



#### Decreased Azithromycin Susceptibility of *Neisseria* gonorrhoeae Isolates in Patients Recently Treated with Azithromycin

Carolien M. Wind,<sup>1</sup> Esther de Vries,<sup>1</sup> Maarten F. Schim van der Loeff,<sup>2,5</sup> Martijn S. van Rooijen,<sup>1</sup> Alje P. van Dam,<sup>3,4</sup> Walter H. B. Demczuk,<sup>7</sup> Irene Martin,<sup>7</sup> and Henry J. C. de Vries<sup>1,6,8</sup>

<sup>1</sup>STI Outpatient Clinic, <sup>2</sup>Research Department, and <sup>3</sup>Public Health Laboratory, Department of Infectious Diseases, Public Health Service Amsterdam, <sup>4</sup>Department of Medical Microbiology, Onze Lieve Vrouwe Gasthuis General Hospital, <sup>5</sup>Department of General Medicine, and <sup>6</sup>Department of Dermatology, Academic Medical Center, University of Amsterdam, The Netherlands; <sup>7</sup>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg; and <sup>8</sup>Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, The Netherlands





## Why Increase Dose of Ceftriaxone? Weight-based Pharmacokinetics

		Mouse model		
Weight	3 mg/kg	5 mg/kg^	10 mg/kg	suggested
50 kg	150 mg	250 mg	500 mg	5 mg/kg dose for susceptible isolate
80 kg*	240 mg	400 mg	800 mg	(MIC 0.008)
100 kg	300 mg	500 mg	1000mg	*U.S. adult
150 kg	450 mg	750 mg	1500mg	average weight:
			-	80 kg

Connolly KL. Antimicrob Agents Chemother 2019;63:e01644–18.

## Gonorrhea Treatment Around the World

Country	Treatment	Comments	
United Kingdom	Ceftriaxone 1g x1	If you have susceptibility data prior to treatment, AND it's susceptible to cipro $\rightarrow$ use cipro 500 mg	
Australia & Europe	Ceftriaxone 500mg x1 Plus Azithromycin 2g		
Japan	Ceftriaxone 1g		



## EXPEDITED PARTNER THERAPY



A 19 yo cisgender man is diagnosed with rectal GC and CT on routine screening. He reports sex with 3 cisgender men in the past 60 days. What should you do for these partners?

- 1. Offer cefixime plus azithromycin as patient-delivered partner therapy (PDPT)
- 2. Offer cefixime plus doxycycline as PDPT
- 3. Do not offer PDPT

## Expedited Partner Therapy (EPT) or Patient-delivered partner therapy (PDPT)

- No states in US prohibit EPT (either allowable or potentially allowable by law/statute in all 50 states)
- Appropriate for partners of patients with GC/CT whose treatment cannot be ensured or is unlikely
  - Not appropriate for syphilis, maybe trichomonas
- Partners in the past 60 days
  - Or if no sex for >60 days, attempt to treat most recent partner(s)
- Previously only recommended for WSM and MSW, due to concerns about missing HIV and syphilis in MSM
  - Now "shared decision making" for EPT for MSM
- Providing patients with packaged oral medications is preferred approach
  - Partners (especially adolescents) may not fill prescriptions

# Expedited Partner Therapy (EPT) Big Changes in 2021

- Partners should be highly encouraged to present for testing and treatment
- BUT if partners will not or cannot:

EPT for exposure to GC and CT:

cefixime 800 mg PO x 1 AND doxycycline 100 mg PO x 7 days\*

EPT for exposure to GC alone: cefixime **800 mg** PO x 1

EPT for exposure to CT alone: doxycycline 100 mg PO x 7 days\*


\*Azithromycin 1 g can be considered but decreased efficacy for rectal CT



## Expedited Partner Therapy: What to Include

#### Information provided with EPT

- Information about medications, allergies & STI
- Advice about complications and when and where to seek care (e.g. PID)
- With new recommendation would also counsel about doxy: pregnancy, GI symptoms, photosensitivity
- Best resource for fact sheets I have found from Oregon Health Authority: <u>https://www.oregon.gov/oha/ph/DISEASE</u> <u>SCONDITIONS/HIVSTDVIRALHEPATITIS</u> /SEXUALLYTRANSMITTEDDISEASE/Pag es/partnertherapy.aspx



https://kingcounty.gov/en/legacy/depts/health/communicable-diseases/hivstd/providers/partner-notification/ept-guidelines.aspx

### How to find anonymous partners met on the internet? Send an email love letter...

STDcheck.com	Home	Find a Lab 🔻	How It Works 🔻	Prices & Packa		
Anonymous STD Test Notification						
Send Anonymous Notif Phone O E-mail	ication	by Phone	e or E-mail			
Phone Number: (000) 867-5309						
Here is the content of the notification text message:						
STDCheck.com - A sexual partner tested positive for an STD & recommends that you also get tested. For details, visit STDcheck.com/notify Text STOP = Opt-Out						
A Send Text						

https://www.stdcheck.com/anonymous-notification.php



## MYCOPLASMA GENITALIUM



## A Case of Persistent Urethritis

- 29-year-old transgender woman presents with burning with urination and meatal discharge x 2 days
- She reports unprotected sex (IAI) approximately 7 days ago
- She is treated empirically for GC/CT with ceftriaxone and doxycycline
- She returns 1 week later reporting ongoing symptoms; initial GC/CT testing has returned negative and she says she has had no sex at all since last visit
- What are possible causes?

#### **Differential Diagnosis of Urethritis**

#### **Gonococcal Urethritis**

Neisseria gonorrhoeae

Non-Gonococcal Urethritis (NGU)

- Chlamydia trachomatis (15-40%)
- Ureaplasma urealyticum
- Mycoplasma genitalium (15-40%)
- Trichomonas vaginalis
- Herpes simplex virus
- Adenovirus
- Other enteric bacteria
- Neisseria meningitidis





## Prevalence of Key Pathogens among Men with Symptomatic Urethritis

Study Site (n)	Gonorrhea	Chlamydia	M. genitalium	Trichomonas
Birmingham, AL (n=235)	33%	23%	30%	7%
Durham, NC (n=93)	42%	32%	25%	8%
Greensboro, NC (n=152)	43%	29%	39%	10%
New Orleans, LA (n=103)	37%	25%	29%	2%
Pittsburgh, PA (n=174)	26%	27%	28%	12%
Seattle, WA (n=157)	35%	25%	29%	2%
Overall	35%	25%	29%	7%


#### More than 1 in 4 men with urethritis have *M. genitalium*

Bachmann LH, CID 2020

## No longer an emerging pathogen: *Mycoplasma genitalium*

- Bacterial slow-growing pathogen, but does not gram stain
- Role in urethritis and cervicitis; also PID but less clear
- No recommendations for routine screening, in 2021 test in persistent urethritis that fails initial treatment, consider for persistent PID/cervicitis
- In 2019 FDA approved 1<sup>st</sup> MG NAAT (*Aptima*) for urine, urethral, penile meatal, endocervical, vaginal specimens
- Ureaplasma and other mycoplasma species of unclear significance
  - Testing/treatment not recommended
- Macrolide and doxy resistance, also some quinolone
  - Macrolide resistance tests may be available to guide therapy soon

# Prevalence of Resistance Mutations in *M. genitalium* among Men with Urethritis




1. 23S rRNA mutation, among those with evaluable results

2. parC mutation, among those with evaluable results

Bachmann LH, CID 2020

## 2021 Urethritis Treatment: Initial and Persistent/Recurrent




- MG macrolide resistance testing may change some of these guidelines, but not yet currently available in US.
- If macrolide sensitive, after doxycycline course, give azithromycin 1 g, then 500 mg daily x 3



## TRICHOMONAS






Courtesy of John Alderete, Ph.D.

A 56 year old woman tells you she has had some yellowgreen vaginal discharge with a strong odor, and she would like it to go away. She denies sexual activity of any kind for over 5 years. Urine NAAT is positive for trichomonas. How should you treat her?

- 1. Metronidazole 2 gm orally once
- 2. Metronidazole 500 mg orally twice daily for 7 days
- 3. It depends whether she has HIV or not

# Typical frothy, yellowish vaginal discharge of trichomoniasis






## Cervicitis due to *Trichomonas vaginalis*

## Strawberry cervix "Colpitis macularis"



## Saline microscopy of *Trichomonas vaginalis* with PMNs



## Trichomoniasis: The "Neglected STD"

- Under appreciated in its importance—most common nonviral STD in US (4-8 million new cases/yr estimated)
  - Not reportable in the US
  - Wider age distribution of 20-45 y
  - Prevalence 3% in US, 15-20% in US black women 30-50 y
  - Very high rates in incarcerated women (9-32%) and men (2-9%) screened
    - 17% in WA DOC pilot screening program at intake (2016)
  - 70-85% asymptomatic, may persist for years
  - Can lead to pre-term delivery, LBW, PID
  - Worldwide—MAJOR implications –multiple studies show increased acquisition of HIV if T. vaginalis infection (2-3 fold)

Muzny C, CID 2015. Soper D, AJOG 2004. NHANES, Sutton, CID 2007.

## T. vaginalis screening/diagnostic testing

#### Screening for *T. vaginalis* is recommended for

- Cisgender women with HIV (entry to care, then annually)
- Cisgender women in correctional settings
- Consider for other high prevalence settings
- Screening for men is not recommended
  - Rare in MSM
- Extragenital T. vaginalis is rare
  - Rectal and oral testing is not recommended!!


#### Diagnostic testing: Patients with vaginal discharge

#### Multiple FDA-cleared NAAT and rapid tests

- Urine, urethral, endocervical (including liquid cytology), vaginal
- Not all tests are approved for men

#### Treatment Consideration: Single dose metronidazole is not as effective as 7 days

- Single dose (2 gm) previously recommended for trich in HIVnegative women, 7-day therapy (500 mg BID) recommended for patients with HIV (CDC TX GL 2015)
- N=623 women randomized 1:1 to single dose MTZ vs 7 day
- Culture TOC, 6-12 days post treatment



#### **Trichomoniasis Treatment 2021**

Change in 2021 STI Treatment Guidelines

Vaginal trichomonas (HIV+/HIV-/pregnant)

Metronidazole 500 mg PO BID x 7d

#### Penile/urethral trichomonas or male partners

Metronidazole 2 g PO single dose

#### **Alternative regimen**


Tinidazole 2 g PO single dose

CDC 2015 STD Treatment Guidelines, ACOG Practice Bulletin 215. OB/GYN Vol 135. Jan 2020

### Metronidazole and Alcohol

- Metronidazole does not actually inhibit acetaldehyde dehydrogenase (as occurs with disulfiram)
- Evidence review: no in vitro or clinical studies, no animal models, and no adverse event reporting
- Refraining from ETOH is unnecessary during treatment

Change in 2021 STI Treatment Guidelines



2021 CDC STI Treatment Guidelines Fjeld H, Raknes G. Tidsskr Nor Laegeforen. 2014;134(17):1661– 3



## WHO NEEDS A TEST OF CURE AND WHO NEEDS RETESTING?



#### Test of Cure vs Retesting

RETEST FOR REINFECTION	Time period	Who
GC/CT/LGV (all sites)	3 m (anytime from 1-12 m ok)	All patients
Trichomonas	3 m (anytime from 1-12 m ok)	Patients w/vaginal infection


TEST OF CURE	Time period	Who
GC (pharynx)	2 weeks	All patients
CT* (cervix)	4 weeks	Pregnant patients only


\*Test of cure for GC in pregnancy not mentioned in the guidelines but experts recommend TOC in this setting

### MPOX, THE VIRUS FORMERLY KNOWN AS MONKEYPOX: CURRENTLY TAKING A BACKSEAT...FOR NOW



## Mpox cases in WA and King County






Don't forget to vaccinate! No current rec to booster No vax if had mpox infection



https://kingcounty.gov/en/legacy/depts/health/mpox/data.aspx https://doh.wa.gov/you-and-your-family/illness-and-disease-z/mpox/mpox-data





# Mpox cases in North Dakota

Data updated on the first Tuesday of every month. Data last refreshed Wednesday. March 06, 2024. Counties with fewer than five cases are not

reported individually but are included in the total case count

Williar





https://www.hhs.nd.gov/public-health-information/diseases-conditions-andimmunization/monkeypox/monkeypox-data-dashboard

Mpox Case County Analysis

State-wide Mpox

Case Summary

6 Total Cases

https://doh.sd.gov/health-data-reports/data-dashboards/mpox-dashboard/





## A NEW TOOL IN OUR PREVENTION TOOLBOX: DOXYPEP




A 24 year old MSM on HIV PrEP comes in to be treated for rectal chlamydia found on routine screening. He had secondary syphilis earlier in the year. How would you counsel him to prevent STIs?

- 1. Always use condoms
- 2. Get the Hep B and HPV vaccines
- 3. Have fewer partners and less sex
- 4. Offer DoxyPEP
- 5. Just get HIV/STI testing and treatment more often

#### What is DoxyPEP?

Intervention: <u>Open label</u> doxycycline 200mg taken as PEP within 72 hours after condomless sexual contact *Maximum of 200 mg every 24 hours* 



#### Inclusion criteria:


- Male sex at birth
- Living with HIV or on PrEP
- ≥ 1 STI in past 12 months
- Condomless sex with ≥ 1 male partner in past 12 months

**STI Testing:** Quarterly 3 site GC/CT testing + RPR, GC culture before treatment

Sites: San Francisco & Seattle HIV & STI clinics

#### DoxyPEP reduced STI incidence by 65%

#### Primary Endpoint: STI incidence per quarter



#### DoxyPEP: What we know

DoxyPEP works very well to prevent STIs in this study population: ↓ by more than **60%** each quarter

↓ in *each* bacterial STI per quarter, including gonorrhea

Need to treat about **5 people** to prevent a quarter with an STI, in a population with a high STI incidence (30% per quarter)

Safe & well tolerated

DoxyPEP: What we are still learning

STI resistance, and will it make DoxyPEP less effective? Especially GC and syphilis

Effect on M. genitalium

Impact on bystander bacteria like Staph aureus, commensal Neisseria, and the gut microbiome

Adherence, sexual behavior...

#### **DoxyPEP Local Guidelines**

HIV/STI/HCV Program Sexual Health Clinic

Ninth and Jefferson Building 908 Jefferson St, 11th Floor Seattle, WA 98104 **206-744-3590** www.kingcounty.gov/health



#### **Guidelines, June 2023**

#### Doxycycline Post-Exposure Prophylaxis (Doxy-PEP) to Prevent Bacterial STIs in Men who Have Sex with Men (MSM) and Transgender Persons who Have Sex with Men

Includes information about who to offer DoxyPEP, counseling messages, dosing and prescribing recs, billing codes, lab monitoring. Also a fantastic fact sheet for patients!

https://cdn.kingcounty.gov/-/media/depts/health/communicable-diseases/documents/hivstd/DoxyPEP-Guidelines.ashx

https://cdn.kingcounty.gov/-/media/depts/health/communicable-diseases/documents/hivstd/DoxyPEPfacts.ashx?la=en&hash=47631D55F34D12F6896792E2B0E975EF

## Monitoring on DoxyPEP

#### Laboratory

- No serious lab abnormalities in DoxyPEP
- Package insert: LFTs, renal function & CBC checked "periodically" when taking doxycycline for a prolonged period
- Take home:
  - No baseline labs needed
  - Consider checking annually




#### STIs

- Screen for STIs every 3 months at all anatomic sites of exposure
  - Can we screen less frequently? May depend on patient factors
- If diagnosed with an STI on doxy-PEP, treat according to the CDC STI treatment guidelines




#### Doxy PEP – How to Take



#### Two 100mg pills of doxycycline ideally within 24 hours but no later than 72 hours after condomless sex

Example: Sex on Sat; take dose of doxy by Tues Example: Sex on Thursday; take dose of doxy by Sunday Example: Sex on Thursday; take dose of doxy by Sunday Up to 72 hours after sex Friday Saturday Sunday Example 2: Daily (or more) sex Sat-Tues; take daily dose of doxy and last dose within 24 hours *but not later than 72 hours* 



No more than 200 mg every 24 hours

### A few rapid fire updates!

- Pelvic Inflammatory Disease: metronidazole no longer considered optional when treating PID
- Gonorrhea prevention: Meningitis B vaccine?

#### And so much more to explore...

- Special populations
- Herpes testing
- Penicillin allergy
- Newer vaginitis diagnostics
- And stay tuned for:
  - Anal cancer screening
  - Meningitis B vaccine to prevent gonorrhea

### Acknowledgments

- Chase Cannon UW, PHSKC Sexual Health Clinic
- Christine Johnston UW, STD PTC
- Raaka Kumbhakar UW
- Lindley Barbee CDC
- Ina Park UCSF, California Prevention Training Center
- Laura Bachmann CDC
- Sancta St. Cyr CDC
- Will Geisler University of Alabama Birmingham
- Sharon Adler UCSF, California Prevention Training Center
- Chris Fox OHSU

## Any <u>Burning</u> Questions?

## OH, I AM SO WORTH THE RASH



## Thank you!!

Hillary Liss hliss@uw.edu 206-744-1035 This Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$3,333,289 with 0% financed with nongovernmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.

